GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...
Though prescribing climate-friendly dry powder inhalers is environmentally sound, some experts warn certain patients may be ...
Actuate’s lead investigational drug product, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways ... that we face significant competition from other biotechnology and pharmaceutical ...
Dynavax is giving up work on its combination vaccine for tetanus, diphtheria and acellular pertussis (Tdap) after mulling phase 1 data for the shot. | Dynavax is giving up on its combination vaccine ...
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...
GSK (GSK) stock was downgraded by Guggenheim Securities to neutral after the company's Q3 revenue decline. Read more here.
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
Cullinan Management (CGEM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...
GSK is setting aside a mid-stage 24-valent pneumococcal vaccine program for adults to instead focus on a preclinical option that covers 30-plus valents, the compa ...
This writer thinks GSK shares appear very cheap after the Q3 results, making him wonder if now's the time for him to invest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback